![CME Programme CSHK mw_menu_data_5564_56eb2b174e5e3.jpg](https://cshk.org/site/CSHK/upload/mw_menu_data/file/mw_menu_data_5564_56eb2b174e5e3.jpg)
CME Programme
-
Non-Regular Activities
To Introduce the Most Advanced Patient-derived Organoids (PDO) Technology for its Clinical Application Potential in Personalized Cancer Drug MatchingDate: 17/05/2023 Enquiries: Invitrocue Hong Kong Limited CME Points Awarded: 1.5 points